Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

NY-ESO-1-derived peptides and their use in cancer therapy and diagnosis

Nov. 23, 1999

StressGen to codevelop HspE7 with NCI for HPV diseases

Nov. 17, 1999

First approval granted for Melacine melanoma therapeutic vaccine

Nov. 5, 1999

Maxamine in combination with IL-2 shows positive results in brain cancer model

Nov. 3, 1999

Celltech Chiroscience development partner files for FDA approval of AML treatment

Nov. 2, 1999

Abbott licenses development, marketing rights to Theragyn from Antisoma

Oct. 29, 1999

Clinical data presented for Avax's autologous cancer vaccines

Oct. 29, 1999

Vical receives orphan drug status for Allovectin-7

Oct. 28, 1999

StessGen begins trial of HspE7 for anal dysplasia

Oct. 27, 1999

Development of OvaRex is now sole focus for AltaRex

Oct. 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...